Payment overview · 2025
General Payments
$293.21
16 reported records · 11 companies
Healthcare provider profile · identity verified
Thomas Merrill, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NORMAN, OK · NPI 1760474605
Verified facts
What the public records show
CMS Open Payments records show Thomas Merrill, M.D. received $293.21 in general payments during 2025 across 16 reported records.
PFIZER INC. accounted for 25.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 584 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $74.94 | 25.6% | 4 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $45.57 | 15.5% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $36.07 | 12.3% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.30 | 8.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.68 | 8.1% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.48 | 5.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.96 | 5.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.69 | 5.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.35 | 4.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.14 | 4.8% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.03 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $293.21 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $56.61 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $56.61 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $56.61 | 3 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $45.57 | 2 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $36.07 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $36.07 | 2 | 2025 |
Source payment records
|
|||||
| MENQUADFI Normalized: menquadfi |
Biological | SANOFI PASTEUR INC. | $36.07 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $25.30 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.68 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 584 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 155 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 133 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
133 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
93 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
98 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
584 | 85 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
28 | 28 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
155 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1105 | 281 |
| Levothyroxine Sodium | Levothyroxine Sodium | 797 | 193 |
| Amlodipine Besylate | Amlodipine Besylate | 613 | 164 |
| Eliquis | Apixaban | 584 | 85 |
| Lisinopril | Lisinopril | 554 | 154 |
| Omeprazole | Omeprazole | 525 | 139 |
| Pantoprazole Sodium | Pantoprazole Sodium | 444 | 114 |
| Potassium Chloride | Potassium Chloride | 403 | 98 |
| Gabapentin | Gabapentin | 398 | 90 |
| Losartan Potassium | Losartan Potassium | 398 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 395 | 103 |
| Furosemide | Furosemide | 348 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 308 | 86 |
| Metoprolol Tartrate | Metoprolol Tartrate | 272 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 272 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 266 | 71 |
| Clopidogrel | Clopidogrel Bisulfate | 250 | 70 |
| Escitalopram Oxalate | Escitalopram Oxalate | 226 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 220 | 60 |
| Citalopram Hbr | Citalopram Hydrobromide | 211 | 47 |
| Metformin Hcl | Metformin Hcl | 211 | 54 |
| Simvastatin | Simvastatin | 210 | 48 |
| Xarelto | Rivaroxaban | 210 | 28 |
| Donepezil Hcl | Donepezil Hcl | 207 | 52 |
| Allopurinol | Allopurinol | 202 | 60 |
| Mirtazapine | Mirtazapine | 199 | 41 |
| Sertraline Hcl | Sertraline Hcl | 191 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 189 | 50 |
| Trazodone Hcl | Trazodone Hcl | 186 | 51 |
| Famotidine | Famotidine | 173 | 37 |
| Meloxicam | Meloxicam | 170 | 48 |
| Memantine Hcl | Memantine Hcl | 169 | 36 |
| Finasteride | Finasteride | 165 | 39 |
| Torsemide | Torsemide | 162 | 39 |
| Tramadol Hcl | Tramadol Hcl | 157 | 42 |
| Gemtesa | Vibegron | 155 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 152 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 56 |
| Carvedilol | Carvedilol | 141 | 43 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 134 | 27 |
| Jardiance | Empagliflozin | 133 | 30 |
| Montelukast Sodium | Montelukast Sodium | 132 | 39 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 128 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 37 |
| Divalproex Sodium | Divalproex Sodium | 121 | 26 |
| Digoxin | Digoxin | 119 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 118 | 27 |
| Metformin Hcl Er | Metformin Hcl | 115 | 34 |
| Bupropion Xl | Bupropion Hcl | 112 | 26 |
| Buspirone Hcl | Buspirone Hcl | 111 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 111 | 25 |
| Pregabalin | Pregabalin | 110 | 30 |
| Alprazolam | Alprazolam | 108 | 27 |
| Myrbetriq | Mirabegron | 106 | 19 |
| Prednisone | Prednisone | 102 | 54 |
| Ezetimibe | Ezetimibe | 100 | 30 |
| Ozempic | Semaglutide | 98 | 24 |
| Alendronate Sodium | Alendronate Sodium | 97 | 35 |
| Clonazepam | Clonazepam | 96 | 22 |
| Levetiracetam | Levetiracetam | 96 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 95 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 94 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 93 | 19 |
| Celecoxib | Celecoxib | 92 | 27 |
| Ondansetron Odt | Ondansetron | 92 | 35 |
| Novolog Flexpen | Insulin Aspart | 90 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 89 | 63 |
| Spironolactone | Spironolactone | 87 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 86 | 34 |
| Glimepiride | Glimepiride | 81 | 27 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 80 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 77 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 28 |
| Estradiol | Estradiol | 75 | 23 |
| Methylprednisolone | Methylprednisolone | 73 | 62 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 72 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 70 | 13 |
| Atenolol | Atenolol | 69 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 69 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | 20 |
| Levofloxacin | Levofloxacin | 67 | 42 |
| Mounjaro | Tirzepatide | 67 | suppressed |
| Januvia | Sitagliptin Phosphate | 64 | suppressed |
| Cephalexin | Cephalexin | 63 | 33 |
| Temazepam | Temazepam | 62 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 61 | 15 |
| Solifenacin Succinate | Solifenacin Succinate | 57 | 15 |
| Enulose | Lactulose | 56 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 56 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 55 | 13 |
| Entresto | Sacubitril/Valsartan | 54 | suppressed |
| Lorazepam | Lorazepam | 54 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 44 |
| Fenofibrate | Fenofibrate Nanocrystallized | 51 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | 19 |
| Synthroid | Levothyroxine Sodium | 51 | 11 |
| Fenofibrate | Fenofibrate | 49 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 48 | 14 |
| Terazosin Hcl | Terazosin Hcl | 47 | 15 |
| Propranolol Hcl | Propranolol Hcl | 46 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 46 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 45 | 12 |
| Clonidine Hcl | Clonidine Hcl | 44 | 17 |
| Irbesartan | Irbesartan | 44 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 28 |
| Azithromycin | Azithromycin | 42 | 32 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 42 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Sucralfate | Sucralfate | 39 | 18 |
| Tresiba Flextouch U-200 | Insulin Degludec | 39 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 38 | suppressed |
| Latanoprost | Latanoprost | 37 | suppressed |
| Olanzapine | Olanzapine | 37 | 11 |
| Ursodiol | Ursodiol | 37 | suppressed |
| Glipizide | Glipizide | 35 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | 13 |
| Meclizine Hcl | Meclizine Hcl | 34 | 14 |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 31 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 31 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 30 | suppressed |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 29 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 29 | suppressed |
| Xifaxan | Rifaximin | 29 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 28 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 28 |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 26 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 25 | suppressed |
| Cefdinir | Cefdinir | 25 | 23 |
| Fentanyl | Fentanyl | 25 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 16 |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 25 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 25 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 24 | 17 |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 15 |
| Vancomycin Hcl | Vancomycin Hcl | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 18 |
| Amoxicillin | Amoxicillin | 22 | 20 |
| Humalog | Insulin Lispro | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 15 |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Nystatin | Nystatin | 18 | 14 |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Glucagon Emergency Kit | Glucagon | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | 12 |
| Zaleplon | Zaleplon | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 11 |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Triazolam | Triazolam | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 14 | suppressed |
| Olanzapine Odt | Olanzapine | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 13 | suppressed |
| Levetiracetam Er | Levetiracetam | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | 11 |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 11 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Ertapenem | Ertapenem Sodium | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 11 | 11 |
| Meprobamate | Meprobamate | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Tymlos | Abaloparatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $293.21 · 16 records | PFIZER INC. | ABRYSVO, AREXVY, BEYFORTUS, COMIRNATY, ELIQUIS, FANAPT, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, GEMTESA, JARDIANCE, MENQUADFI, OTEZLA, PREVNAR 20, REPATHA, SHINGRIX, TERIPARATIDE, UNITHROID, WATCHMAN Access System, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error